Drugs / autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine
autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00101309 | Nov 2004 → Nov 2007 | neuroblastoma, sarcoma | Milton S. Hershey Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101309 ↗ |
| Modality | Vaccine | “Vaccination: Patients receive vaccine comprising autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells” NCT00101309 ↗ |
| Route | Subcutaneous | “autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells subcutaneously (SC) once on days 0, 14, and 28” NCT00101309 ↗ |